EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:31772 - levobupivacaine hydrochloride (anhydrous)
| Formula | C18H28N2O.HCl |
| Net Charge | 0 |
| Average Mass | 324.896 |
| Monoisotopic Mass | 324.19684 |
| SMILES | CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl |
| InChI | InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H/t16-;/m0./s1 |
| InChIKey | SIEYLFHKZGLBNX-NTISSMGPSA-N |
| Roles Classification |
|---|
| Chemical Role: | amphiphile A surfactant molecule possessing both hydrophilic and lipophilic properties. |
| Biological Roles: | adrenergic antagonist An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. EC 3.1.1.8 (cholinesterase) inhibitor An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8). EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Ca2+-transporting ATPase (EC 3.6.3.8). |
| Applications: | local anaesthetic Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block. adrenergic antagonist An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has part levobupivacaine(1+) (CHEBI:77458) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role adrenergic antagonist (CHEBI:37887) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role amphiphile (CHEBI:59941) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role EC 3.1.1.8 (cholinesterase) inhibitor (CHEBI:37733) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role EC 3.6.3.8 (Ca2+-transporting ATPase) inhibitor (CHEBI:60186) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) has role local anaesthetic (CHEBI:36333) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) is a 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride (CHEBI:77441) |
| levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) is enantiomer of dextrobupivacaine hydrochloride (anhydrous) (CHEBI:77442) |
| Incoming Relation(s) |
| bupivacaine hydrochloride (anhydrous) (CHEBI:31322) has part levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) |
| levobupivacaine hydrochloride hydrate (CHEBI:77453) has part levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) |
| dextrobupivacaine hydrochloride (anhydrous) (CHEBI:77442) is enantiomer of levobupivacaine hydrochloride (anhydrous) (CHEBI:31772) |
| IUPAC Names |
|---|
| (2S)-1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium chloride |
| (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride |
| Synonyms | Source |
|---|---|
| (−)-bupivacaine hydrochloride | ChEBI |
| (S)-1-butyl-2',6'-pipecoloxylidide hydrochloride | ChEBI |
| levobupivacaine HCl | ChemIDplus |
| levobupivacaine hydrochloride | ChEBI |
| levobupivacaine monohydrochloride | ChEBI |
| Brand Name | Source |
|---|---|
| Chirocaine | ChEBI |
| Registry Numbers | Sources |
|---|---|
| Reaxys:8879953 | Reaxys |
| CAS:27262-48-2 | ChemIDplus |
| CAS:27262-48-2 | KEGG DRUG |
| Citations |
|---|